Mice Develop Effective but Delayed Protective Immune Responses When Immunized as Neonates either Intranasally with Nonliving VP6/LT(R192G) or Orally with Live Rhesus Rotavirus Vaccine Candidates

ABSTRACT Rotavirus vaccines are delivered early in life, when the immune system is immature. To determine the effects of immaturity on responses to candidate vaccines, neonatal (7 days old) and adult mice were immunized with single doses of either Escherichia coli-expressed rotavirus VP6 protein and the adjuvant LT(R192G) or live rhesus rotavirus (RRV), and protection against fecal rotavirus shedding following challenge with the murine rotavirus strain EDIM was determined. Neonatal mice immunized intranasally with VP6/LT(R192G) were unprotected at 10 days postimmunization (dpi) and had no detectable rotavirus B-cell (antibody) or CD4+ CD8+ T-cell (rotavirus-inducible, Th1 [gamma interferon and interleukin-2 {IL-2}]-, Th2 [IL-5 and IL-4]-, or ThIL-17 [IL-17]-producing spleen cells) responses. However, by 28 and 42 dpi, these mice were significantly (P ≥ 0.003) protected and contained memory rotavirus-specific T cells but produced no rotavirus antibody. In contrast, adult mice were nearly fully protected by 10 dpi and contained both rotavirus immunoglobulin G and memory T cells. Neonates immunized orally with RRV were also less protected (P = 0.01) than adult mice by 10 dpi and produced correspondingly less rotavirus antibody. Both groups contained few rotavirus-specific memory T cells. Protection levels by 28 dpi for neonates or adults were equal, as were rotavirus antibody levels. This report introduces a neonatal mouse model for active protection studies with rotavirus vaccines. It indicates that, with time, neonatal mice develop full protection after intranasal immunization with VP6/LT(R192G) or oral immunization with a live heterologous rotavirus and supports reports that protection depends on CD4+ T cells or antibody, respectively.

[1]  R. Ward,et al.  Protection against rotavirus shedding after intranasal immunization of mice with a chimeric VP6 protein does not require intestinal IgA. , 2006, Virology.

[2]  J. Heyse,et al.  Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. , 2006, The New England journal of medicine.

[3]  T. Vesikari,et al.  Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. , 2006, The New England journal of medicine.

[4]  J. Shellito,et al.  Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae , 2005, The Journal of experimental medicine.

[5]  C. Mason,et al.  Pulmonary Interleukin-23 Gene Delivery Increases Local T-Cell Immunity and Controls Growth of Mycobacterium tuberculosis in the Lungs , 2005, Infection and Immunity.

[6]  P. Lambert,et al.  Can successful vaccines teach us how to induce efficient protective immune responses? , 2005, Nature Medicine.

[7]  E. Butcher,et al.  Chapter 34 – Lymphocyte Homing: Chemokines and Adhesion Molecules in T cell and IgA Plasma Cell Localization in the Mucosal Immune System , 2005 .

[8]  J. Bienenstock,et al.  Chapter 20 – Bronchus-Associated Lymphoid Tissues , 2005 .

[9]  M. G. Ferrari,et al.  Mucosal adjuvants. , 2005, Current pharmaceutical design.

[10]  R. Ward,et al.  Intranasal administration of an Escherichia coli-expressed codon-optimized rotavirus VP6 protein induces protection in mice. , 2004, Protein expression and purification.

[11]  T. Vesikari,et al.  A Rotavirus Vaccine for Prophylaxis of Infants Against Rotavirus Gastroenteritis , 2004, The Pediatric infectious disease journal.

[12]  A. Lindén,et al.  Interleukin-17 family members and inflammation. , 2004, Immunity.

[13]  C. Leclerc,et al.  Neonatal adaptive immunity comes of age , 2004, Nature Reviews Immunology.

[14]  B. Adkins,et al.  Murine Neonatal Lymphocytes Show Rapid Early Cell Cycle Entry and Cell Division1 , 2003, The Journal of Immunology.

[15]  Mark A. Miller,et al.  Global Illness and Deaths Caused by Rotavirus Disease in Children , 2003, Emerging infectious diseases.

[16]  P. Lambert,et al.  Unresponsiveness to Lymphoid-Mediated Signals at the Neonatal Follicular Dendritic Cell Precursor Level Contributes to Delayed Germinal Center Induction and Limitations of Neonatal Antibody Responses to T-Dependent Antigens 1 , 2003, The Journal of Immunology.

[17]  R. Ward,et al.  Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotaviruses. , 2002, Vaccine.

[18]  H. Greenberg,et al.  Heterologous Protection Induced by the Inner Capsid Proteins of Rotavirus Requires Transcytosis of Mucosal Immunoglobulins , 2002, Journal of Virology.

[19]  B. Prasad,et al.  Inhibition of rotavirus replication by a non-neutralizing, rotavirus VP6-specific IgA mAb. , 2002, The Journal of clinical investigation.

[20]  C. Pénit,et al.  Naive T cells proliferate strongly in neonatal mice in response to self-peptide/self-MHC complexes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[21]  R. Ward,et al.  CD4 T Cells Are the Only Lymphocytes Needed To Protect Mice against Rotavirus Shedding after Intranasal Immunization with a Chimeric VP6 Protein and the Adjuvant LT(R192G) , 2002, Journal of Virology.

[22]  C. Siegrist Neonatal and early life vaccinology. , 2001, Vaccine.

[23]  Alan D. Roberts,et al.  Protection from Respiratory Virus Infections Can Be Mediated by Antigen-Specific Cd4+ T Cells That Persist in the Lungs , 2001, The Journal of experimental medicine.

[24]  R. Ward,et al.  Functional Mapping of Protective Domains and Epitopes in the Rotavirus VP6 Protein , 2000, Journal of Virology.

[25]  R. Glass,et al.  Serum antibody as a marker of protection against natural rotavirus infection and disease. , 2000, The Journal of infectious diseases.

[26]  H. Friess,et al.  IL-17 Stimulates Intraperitoneal Neutrophil Infiltration Through the Release of GROα Chemokine from Mesothelial Cells1 , 2000, The Journal of Immunology.

[27]  M. Estes,et al.  Intranasal Administration of 2/6-Rotavirus-Like Particles with Mutant Escherichia coli Heat-Labile Toxin (LT-R192G) Induces Antibody-Secreting Cell Responses but Not Protective Immunity in Gnotobiotic Pigs , 2000, Journal of Virology.

[28]  Y. Umesaki,et al.  Structure of the intestinal flora responsible for development of the gut immune system in a rodent model. , 2000, Microbes and infection.

[29]  J. Bonnefoy,et al.  CD4+ T-Cell-Mediated Antiviral Protection of the Upper Respiratory Tract in BALB/c Mice following Parenteral Immunization with a Recombinant Respiratory Syncytial Virus G Protein Fragment , 2000, Journal of Virology.

[30]  B. Adkins Development of Neonatal Th1/Th2 Function , 2000, International reviews of immunology.

[31]  C. Siegrist Vaccination in the Neonatal Period and Early Infancy , 2000, International reviews of immunology.

[32]  M. Sarzotti,et al.  T cell immunity in neonates , 2000, Immunologic research.

[33]  R. Ward,et al.  Antibody-Independent Protection against Rotavirus Infection of Mice Stimulated by Intranasal Immunization with Chimeric VP4 or VP6 Protein , 1999, Journal of Virology.

[34]  R. Ward,et al.  Antibody-Dependent and -Independent Protection following Intranasal Immunization of Mice with Rotavirus Particles , 1999, Journal of Virology.

[35]  J. Cebra,et al.  Influences of microbiota on intestinal immune system development. , 1999, The American journal of clinical nutrition.

[36]  P. Doherty,et al.  CD4(+) T cell-mediated control of a gamma-herpesvirus in B cell-deficient mice is mediated by IFN-gamma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Banchereau,et al.  Interleukin-17 activates human renal epithelial cells in vitro and is expressed during renal allograft rejection. , 1998, Journal of the American Society of Nephrology : JASN.

[38]  D. Brooks,et al.  Critical Role for CD4+ T Cells in Controlling Retrovirus Replication and Spread in Persistently Infected Mice , 1998, Journal of Virology.

[39]  M. Estes,et al.  Rotavirus 2/6 Viruslike Particles Administered Intranasally with Cholera Toxin, Escherichia coli Heat-Labile Toxin (LT), and LT-R192G Induce Protection from Rotavirus Challenge , 1998, Journal of Virology.

[40]  R. Ward,et al.  Evidence that resolution of rotavirus infection in mice is due to both CD4 and CD8 cell-dependent activities , 1997, Journal of virology.

[41]  M. Estes,et al.  Rotavirus virus-like particles administered mucosally induce protective immunity , 1997, Journal of virology.

[42]  D. Bass,et al.  Interferon gamma and interleukin 1, but not interferon alfa, inhibit rotavirus entry into human intestinal cell lines , 1997, Gastroenterology.

[43]  R. Ward,et al.  Particle bombardment-mediated DNA vaccination with rotavirus VP6 induces high levels of serum rotavirus IgG but fails to protect mice against challenge. , 1997, Virology.

[44]  H. Greenberg,et al.  Heterotypic protection following oral immunization with live heterologous rotaviruses in a mouse model. , 1997, The Journal of infectious diseases.

[45]  J. Seidman,et al.  Lack of association of secretory component with IgA in J chain-deficient mice. , 1996, Journal of immunology.

[46]  J. Banchereau,et al.  T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines , 1996, The Journal of experimental medicine.

[47]  L. Saif,et al.  Systematic and intestinal antibody-secreting cell responses and correlates of protective immunity to human rotavirus in a gnotobiotic pig model of disease , 1996, Journal of virology.

[48]  L. Saif,et al.  Development of mucosal and systemic lymphoproliferative responses and protective immunity to human group A rotaviruses in a gnotobiotic pig model , 1996, Clinical and diagnostic laboratory immunology.

[49]  H. Greenberg,et al.  Protective Effect of Rotavirus VP6-Specific IgA Monoclonal Antibodies That Lack Neutralizing Activity , 1996, Science.

[50]  R. Ward,et al.  Effector functions of antibody and CD8+ cells in resolution of rotavirus infection and protection against reinfection in mice. , 1995, Virology.

[51]  H. Greenberg,et al.  Role of B cells and cytotoxic T lymphocytes in clearance of and immunity to rotavirus infection in mice , 1995, Journal of virology.

[52]  R. Ward,et al.  Long-term production of rotavirus antibody and protection against reinfection following a single infection of neonatal mice with murine rotavirus. , 1995, Virology.

[53]  B. Rouse,et al.  Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity against herpes simplex virus through CD4+ Th1+ T cells , 1995, Journal of virology.

[54]  G. Splitter,et al.  Picornavirus-specific CD4+ T lymphocytes possessing cytolytic activity confer protection in the absence of prophylactic antibodies , 1995, Journal of virology.

[55]  J. Clements,et al.  Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity , 1995, Infection and immunity.

[56]  H. Greenberg,et al.  Comparison of mucosal and systemic humoral immune responses and subsequent protection in mice orally inoculated with a homologous or a heterologous rotavirus , 1994, Journal of virology.

[57]  R. Ward,et al.  Active immunity against rotavirus infection in mice is correlated with viral replication and titers of serum rotavirus IgA following vaccination. , 1994, Virology.

[58]  R. Glass,et al.  Protection conferred by neonatal rotavirus infection against subsequent rotavirus diarrhea. , 1993, The Journal of infectious diseases.

[59]  M. Estes,et al.  Fecal antibody responses to symptomatic and asymptomatic rotavirus infections. , 1993, The Journal of infectious diseases.

[60]  R. Ward,et al.  Active protection against rotavirus infection of mice following intraperitoneal immunization. , 1992, Virology.

[61]  G. Barnes,et al.  Role of coproantibody in clinical protection of children during reinfection with rotavirus , 1992, Journal of clinical microbiology.

[62]  R. Ward,et al.  Evidence that active protection following oral immunization of mice with live rotavirus is not dependent on neutralizing antibody. , 1992, Virology.

[63]  L. Saif,et al.  Prevention of Human Rotavirus-Induced Diarrhea in Gnotobiotic Piglets using Bovine Antibody , 1992, The Journal of infectious diseases.

[64]  D. Sack,et al.  Seroepidemiologic evaluation of antibodies to rotavirus as correlates of the risk of clinically significant rotavirus diarrhea in rural Bangladesh. , 1992, The Journal of infectious diseases.

[65]  R. Ward,et al.  Development of an improved method for measuring neutralizing antibody to rotavirus. , 1991, Journal of virological methods.

[66]  Gary J. Nabel,et al.  New Generation Vaccines , 1990 .

[67]  R. Ward,et al.  Development of an adult mouse model for studies on protection against rotavirus. , 1990, Journal of virology.

[68]  D. Bernstein,et al.  Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. , 1989, The Journal of infectious diseases.

[69]  K. Taniguchi,et al.  PROTECTIVE EFFECT OF NATURALLY ACQUIRED HOMOTYPIC AND HETEROTYPIC ROTAVIRUS ANTIBODIES , 1986, The Lancet.

[70]  R. Feigin,et al.  Textbook of Pediatric Infectious Diseases , 1986 .

[71]  P. Offit,et al.  Protection against rotavirus-induced gastroenteritis in a murine model by passively acquired gastrointestinal but not circulating antibodies , 1985, Journal of virology.

[72]  J. Bienenstock Bronchus-associated lymphoid tissue. , 1985, International archives of allergy and applied immunology.

[73]  G. Barnes,et al.  Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. , 1983, The New England journal of medicine.

[74]  A. Whitelaw,et al.  Passive immunity in calf rotavirus infections: maternal vaccination increases and prolongs immunoglobulin G1 antibody secretion in milk , 1980, Infection and immunity.